Insider Selling: Medline (NASDAQ:MDLN) Major Shareholder Sells $9,609,548.02 in Stock

Medline (NASDAQ:MDLN) major shareholder Private Ltd Gic sold 271,994 shares of the stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $35.33, for a total value of $9,609,548.02. Following the sale, the insider directly owned 24,992,766 shares in the company, valued at $882,994,422.78. This trade represents a 1.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Private Ltd Gic also recently made the following trade(s):

• On Wednesday, August 5th, Private Ltd Gic sold 1,976,618 shares of Medline stock. The stock was sold at an average price of $35.60, for a total value of $70,367,600.80.

Medline Stock Up 2.1%

MDLN stock traded up $0.72 during trading on Friday, reaching $35.23. 8,293,636 shares of the company traded hands, compared to its average volume of 7,380,132. The business has a 50 day simple moving average of $38.24 and a 200 day simple moving average of $41.77. Medline has a 12 month low of $32.81 and a 12 month high of $50.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.51 and a current ratio of 4.41. The company has a market capitalization of $46.28 billion and a price-to-earnings ratio of 110.09.

Medline (NASDAQ:MDLN) last announced its earnings results on Wednesday, August 5th. The company reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.32 by $0.18. The firm had revenue of $7.68 billion during the quarter. On average, equities research analysts anticipate that Medline will post 1.49 earnings per share for the current fiscal year.

Medline News Roundup

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported second-quarter earnings of $0.50 per share, exceeding the $0.32 analyst consensus, while revenue reached $7.69 billion. The company also raised its 2026 organic-sales growth forecast to 9%–10%, signaling continued demand for its medical products. Medline Q2 Earnings Snapshot Medline Raises 2026 Organic Sales Outlook
• Positive Sentiment: BTIG reiterated a Buy rating and $55 price target, citing robust growth and viewing current headwinds as transitory. At that target, the shares would have substantial potential upside from recent trading levels. BTIG Medline Rating
• Neutral Sentiment: Truist lowered its price target from $56 to $47, and Stifel reduced its target from $50 to $45, but both firms maintained Buy ratings. The target cuts reflect increased caution, while the continued recommendations indicate analysts still see meaningful long-term upside. Truist Price Target Update Stifel Price Target Update
• Negative Sentiment: Medline lowered its 2026 adjusted EBITDA forecast to $3.3 billion–$3.4 billion despite the sales outlook increase. The weaker profit guidance has weighed on the stock because it suggests margin pressure or higher costs and offsets the quarterly earnings beat. Medline Falls After EBITDA Outlook Cut
• Negative Sentiment: Several law firms, including Kaplan Fox and Kessler Topaz, announced investigations into potential securities-law violations involving Medline. The actions follow an FDA warning letter reportedly identifying significant violations. These announcements create legal, regulatory and reputational risks, although the investigations do not establish wrongdoing. Kaplan Fox Medline Investigation Kessler Topaz Medline Investigation

Hedge Funds Weigh In On Medline

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Sound Income Strategies LLC purchased a new stake in shares of Medline in the fourth quarter valued at approximately $25,000. GAMMA Investing LLC increased its stake in shares of Medline by 68.3% during the second quarter. GAMMA Investing LLC now owns 626 shares of the company’s stock worth $25,000 after purchasing an additional 254 shares in the last quarter. Entrust Financial LLC purchased a new stake in shares of Medline during the fourth quarter worth about $26,000. NBC Securities Inc. acquired a new position in shares of Medline during the 4th quarter worth about $28,000. Finally, Whipplewood Advisors LLC purchased a new position in Medline in the 1st quarter valued at about $30,000.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on MDLN. BNP Paribas Exane reduced their price target on Medline from $49.00 to $40.00 and set a “neutral” rating on the stock in a research report on Thursday, May 14th. Deutsche Bank Aktiengesellschaft set a $37.00 target price on Medline in a research note on Thursday. Tigress Financial raised their price target on Medline from $60.00 to $62.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. Robert W. Baird set a $42.00 price target on Medline in a research note on Thursday. Finally, Truist Financial decreased their price objective on shares of Medline from $56.00 to $47.00 and set a “buy” rating for the company in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $48.50.

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.